Please login to the form below
PD-L1/ PD-1 inhibitor
This page shows the latest PD-L1/ PD-1 inhibitor news and features for those working in and with pharma, biotech and healthcare.
Merck shares positive late-stage results for Welireg in advanced kidney cancer
RCC that has progressed following PD-1/L1 checkpoint inhibitor and vascular endothelial growth factor-tyrosine kinase inhibitor (VEGF-TKI) therapies. ... Patients with advanced RCC face low survival rates, and for those whose cancer progresses following
Latest news
-
AstraZeneca announces positive phase 3 results for Tagrisso combination in lung cancer
Interim results from the phase 3 AEGEAN study, which is assessing the PD-1/L1 inhibitor in combination with neoadjuvant chemotherapy before surgery and as a monotherapy after surgery, showed the
-
AstraZeneca presents positive phase 3 results for Imfinzi regimen in lung cancer
Interim results from the AEGEAN study, which is assessing the PD-1/L1 inhibitor in combination with neoadjuvant chemotherapy before surgery and as a monotherapy after surgery, showed the regimen reduced ... Imfinzi is a human monoclonal antibody that
-
Gilead’s Trodelvy shows promise in phase 2 bladder cancer study
In cohort one, which assessed mUC patients whose cancer had progressed after platinum-based chemotherapy and checkpoint inhibitor therapy (CPI), Trodelvy was associated with a 10.9 months median overall survival, ... The drug has already received
-
Regeneron’s fianlimab/Libtayo combination shows positive results in advanced melanoma treatment
L1 inhibitor (PD-1/PD-L1-naïve) and one of patients who had received prior PD-1 or PD-L1 inhibitor therapy (PD-1/PD-L1-experienced). ... The objective response rate (ORR) in the PD-1/PD-L1-experienced cohort was 13%.
-
Trial failure for bintrafusp alfa casts doubt on GSK/Merck KGaA’s cancer alliance
Bintrafusp alfa is part of a new wave of bispecific antibodies that are currently being developed by a number of companies as potential successors to the PD-1/PD-L1 inhibitor ... class. The molecule is designed to simultaneously target two
More from news
Approximately 1 fully matching, plus 64 partially matching documents found.
Latest Intelligence
-
Immuno-oncology in 2019: the rapid evolution continues
cells to identify and fight cancer: the PD-1 and PD-L1 checkpoint inhibitor immunotherapies. ... PD-1/PD-L1 inhibitors: Keytruda is King, but the market is developing fast.
More from intelligence
Approximately 0 fully matching, plus 1 partially matching documents found.
Subscribe to our email news alerts
- FDA approves two cell-based gene therapies for sickle cell disease
- Pfizer’s Elrexfio granted EC approval for relapsed and refractory multiple myeloma
- New economic data reveals risk of disincentivising UK life sciences growth
- WHO countries hold seventh INB meeting to prevent global pandemics
- The start of a beautiful friendship
- The future of patient partnerships
No results were found
PMHub
Avalere Health
Avalere Health is a leading global commercialization partner for the biopharmaceutical, medical technology, and wellness industries. Working from advisory to...
Latest intelligence
- Virtual care – negotiating barriers to adoption offers glimpses of an exciting future
- Digital tools and innovative healthcare promise to address pressing healthcare issues if they can satisfy concerns over access, security and affordability...
- Clinical Trials Investigator and Patient Engagement Planning: A Customer Story
- ...
- New Playbook Alert: Virtual Patient Engagement
- ...
